PROGNOMICS LTD

Their core work

ProGnomics is a Swansea-based SME specializing in biomarker diagnostics and biosensor technologies, with deep involvement in graphene-based applications. Their core work bridges biological sensing — particularly blood-based diagnostic tools — with advanced 2D materials like graphene. They contribute diagnostic and sensing expertise to large-scale European graphene initiatives while also pursuing their own biomedical diagnostic development, notably for early-stage Alzheimer's detection.

What they specialise in

How they've shifted over time

ProGnomics entered H2020 through the Graphene Flagship (GrapheneCore1, 2016) and a standalone Alzheimer's diagnostics project (BBDiag, 2017), combining materials science with biomedical sensing from the outset. In the later period (2018-2024), their involvement deepened into applied graphene domains — composite materials, pilot line manufacturing, and specific application areas like sensors and photonics. The trajectory shows a clear shift from foundational graphene research toward commercialization-ready applications, particularly in sensing and pilot-scale production.

ProGnomics is moving from research participation toward manufacturing-ready graphene applications, making them increasingly relevant for partners seeking to bring 2D material-based products to market.

How they like to work

ProGnomics operates exclusively as a participant, never as coordinator, which is typical for a specialized SME contributing niche expertise to large consortia. With 262 unique partners across 25 countries, their network is vast — but this is largely a consequence of the Graphene Flagship's massive consortium structure rather than independently built relationships. They function as a specialist contributor embedded in Europe's largest graphene research ecosystem, offering focused biosensing and diagnostic capabilities within broader programs.

Through the Graphene Flagship and related projects, ProGnomics has worked with 262 partners across 25 countries, giving them access to virtually all major European graphene research groups and industry players. Their network is wide but Flagship-driven rather than independently curated.

What sets them apart

ProGnomics sits at a rare intersection: they combine biological diagnostics expertise (blood biomarkers, Alzheimer's detection) with deep integration into the Graphene Flagship ecosystem. This makes them one of very few SMEs that can translate graphene's material properties into working biosensor and diagnostic applications. For any consortium needing to bridge 2D materials with real-world biomedical sensing, they bring both the domain knowledge and an established track record within Europe's premier graphene program.

Highlights from their portfolio

• GrapheneCore1
  Their largest single EC contribution (EUR 395,826), marking their entry into the Graphene Flagship — Europe's biggest-ever research initiative on a single material.
• BBDiag
  Their only non-Flagship project, revealing their independent biomedical identity: developing blood-based diagnostic tools for early-stage Alzheimer's disease.
• 2D-EPL
  Represents their most recent and forward-looking work — an experimental pilot line for graphene, signaling a shift from research to manufacturing scale-up.